Company Description
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1...
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
Valuation
Price to Sales Ratio
14.98
Price to Book Ratio
2.00
Enterprise Value to EBITDA
-0.01
Enterprise Value to Sales
0.07
Efficiency
Total Asset Turnover
0.09
Liquidity
Current Ratio
5.07
Quick Ratio
5.01
Cash Ratio
4.34
Profitability
Gross Margin
-152.96
Operating Margin
-901.15
Pretax Margin
-900.94
Net Margin
-900.94
Return on Assets
-84.77
Return on Equity
-109.37
Return on Total Capital
-107.89
Capital Structure
Total Debt to Total Assets
0.88
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. Nathan Scott Fine | 64 | 2014 | Executive Chairman & Chief Executive Officer |
Dr. Jeffrey L. Tate | 61 | 2010 | Director, Chief Operating & Quality Officer |
Mr. Joshua M. Fine | 39 | 2014 | Chief Financial Officer & Secretary |
Dr. Lise Lund Kjems | - | 2021 | Chief Medical Officer |
Mr. Michael Lisjak | 46 | 2019 | Senior Vice President-Business Development |
Insider Actions
11/25/2020 |
Joshua M. Fine Chief Financial Officer |
15,000 | Acquisition at $0.08 per share. | 1,200 |
11/23/2020 |
Joshua M. Fine Chief Financial Officer |
10,000 | Acquisition at $0.08 per share. | 800 |
09/30/2020 |
Armistice Capital LLC |
0 | Disposition at $0 per share. | 0 |
09/30/2020 |
Armistice Capital LLC |
5,500 | Disposition at $0.13 per share. | 715 |
09/29/2020 |
Armistice Capital LLC |
0 | Disposition at $0 per share. | 0 |
09/29/2020 |
Armistice Capital LLC |
5,000 | Disposition at $0.14 per share. | 700 |
09/28/2020 |
Armistice Capital LLC |
0 | Disposition at $0 per share. | 0 |
09/28/2020 |
Armistice Capital LLC |
4,966 | Disposition at $0.13 per share. | 645 |
09/24/2020 |
Armistice Capital LLC |
0 | Disposition at $0 per share. | 0 |
09/24/2020 |
Armistice Capital LLC |
38,257 | Disposition at $0.13 per share. | 4,973 |
09/23/2020 |
Armistice Capital LLC |
0 | Disposition at $0 per share. | 0 |
09/23/2020 |
Armistice Capital LLC |
50,000 | Disposition at $0.14 per share. | 7,000 |
09/22/2020 |
Armistice Capital LLC |
0 | Disposition at $0 per share. | 0 |
09/22/2020 |
Armistice Capital LLC |
17,000 | Disposition at $0.15 per share. | 2,550 |
09/21/2020 |
Armistice Capital LLC |
0 | Disposition at $0 per share. | 0 |
09/21/2020 |
Armistice Capital LLC |
100,000 | Disposition at $0.15 per share. | 15,000 |
09/16/2020 |
Armistice Capital LLC |
0 | Disposition at $0 per share. | 0 |
09/16/2020 |
Armistice Capital LLC |
125,000 | Disposition at $0.16 per share. | 20,000 |
MarketWatch News on CYTH
-
Cyclo Therapeutics stock price target cut to $5 from $10 at Maxim Group
- Tomi Kilgore
-
Cyclo Therapeutics stock price target cut to $16 from $25 at Maxim Group
- Tomi Kilgore
-
Cyclo Therapeutics stock price target raised to $25 from $12 at Maxim Group
- Tomi Kilgore
-
Cyclo Therapeutics started at buy with $12 stock price target at Maxim Group
- Tomi Kilgore
Other News on CYTH
-
Cyclo Therapeutics reports Q3 results
- Seeking Alpha
-
10-Q: CYCLO THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Cyclo Therapeutics (CYTH) Investor Presentation - Slideshow
- Seeking Alpha
-
10-Q: CYCLO THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Cyclo Therapeutics (CYTH) Investor Presentation - Slideshow
- Seeking Alpha
-
10-Q: CYCLO THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Hypotheses Underlying Alzheimer's Drug Development
- Seeking Alpha
-
Pathways Impacting Alzheimer's Disease Drug Development
- Seeking Alpha
-
Cyclo Therapeutics (CYTH) Investor Presentation - Slideshow
- Seeking Alpha
-
10-K: CYCLO THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Anti-Amyloid Drugs: The Failure Of Success
- Seeking Alpha
-
RDHL, ARDX and BRFS among pre market gainers
- Seeking Alpha
-
SAVA, CEI and EYES among mid-day movers
- Seeking Alpha
-
Rivian Automotive, DLocal, StoneCo among premarket losers' pack
- Seeking Alpha
-
Cyclo Therapeutics secures $12M capital through equity raise
- Seeking Alpha
- Loading more headlines...